Structure-inspired design of Nsp8-based protein inhibitors to suppress SARS-CoV-2 replication
Preprint
Abstract
SARS-CoV-2 relies on a conserved RNA-dependent RNA polymerase (RdRp) complex composed of nsp12 and its cofactors nsp7 and nsp8 to replicate its RNA genome. Whereas most antiviral strategies target viral enzymes or surface proteins directly, an alternative approach is to disrupt the assembly or function of an essential viral molecular machine using a defective component derived from the pathogen itself. Here, guided by structural analyses of the nsp12–nsp7–nsp8 replication complex, we designed truncated nsp8 proteins that retain the ability to associate with nsp12 but are defective in engaging RNA. Using a purified nsp12–nsp7–nsp8 system capable of RNA primer extension, we show that selected truncated nsp8 variants inhibit polymerase activity when introduced into an otherwise functional complex. These results are consistent with a competitive mechanism in which the defective nsp8 variants associate with nsp12 and interfere with incorporation or function of wild-type nsp8, thereby compromising formation of a productive replication complex. To further explore this strategy, we used structure-guided in silico analysis of the nsp8– nsp12 interface to identify interaction hotspots and screened corresponding single-amino-acid substitutions. Several variants exhibited enhanced inhibitory activity in the reconstituted polymerase assay. Together, these findings establish a proof-of-concept strategy in which a structurally engineered, pathogen-derived protein can act as a dominant-negative inhibitor of an essential viral replication machinery. This approach provides a framework for developing protein- or peptide-based inhibitors that target conserved protein–protein interactions within viral replication complexes.Keywords
Funding Information
- Academia Sinica (AS-IDR-112-03)
This publication has 20 references indexed in Scilit:
- Therapeutic applications of interface-mimicking peptides for targeting the SARS-CoV-2 NSP12-NSP8 RdRp complexMolecular Therapy, 2025
- Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7Molecular Therapy Nucleic Acids, 2025
- AlphaFold Ensemble Competition Screens Enable Peptide Binder Design with Single-Residue SensitivityACS Chemical Biology, 2024
- A molnupiravir-associated mutational signature in global SARS-CoV-2 genomesNature, 2023
- SARS-CoV-2 variants with NSP12 P323L/G671S mutations display enhanced virus replication in ferret upper airways and higher transmissibilityCell Reports, 2023
- Ranking Peptide Binders by Affinity with AlphaFold**Angewandte Chemie International Edition, 2023
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivirNature Communications, 2021
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020